NCT04822584View on ClinicalTrials.gov

Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

April 26, 2023

Study Completion Date

April 26, 2023

Conditions

Vitiligo

Interventions

DRUG

Baricitinib Oral Product

Baricitinib 4 mg/day orally for 36 weeks

DRUG

Placebo

Placebo once a day orally for 36 weeks

Trial Locations (4)

33075

Service de Dermatologie - Hôpital Saint-André, Bordeaux

94010

Service de dermatologie - Hôpital Henri Mondor - EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), Créteil

06000

Centre Hospitalier Universitaire de Nice - Service de Dermatologie, Nice

31059 cedex 9

Service de dermatologie Centre de Référence des Maladies Rares de la Peau et des muqueuses d'origine génétique - Hôpital Larrey, Toulouse

All Listed Sponsors

lead

University Hospital, Bordeaux

OTHER

NCT04822584 - Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo | Biotech Hunter | Biotech Hunter